$AMPH

A peer comparison of Q2 results in generic pharmaceuticals says the four tracked companies beat analysts’ revenue consensus by 2.6% on average, but shares fell 5.6% since reporting. ANI Pharmaceuticals (ANIP) revenue was $266m (+25.9%), EPS beat, but full-year revenue guidance missed; stock down 9.1% to $75.12. Amphastar (AMPH) revenue $183.9m (+5.4%) beat; stock up 2.3% to $20.28. Viatris (VTRS) revenue $3.76b (+4.9%) beat; stock down 7.6% to $16.32. Amneal (AMRX) revenue $796.2m (+9.9%) beat;

Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.

Amphastar Pharmaceuticals (AMPH) reported Q2 revenue of $183.9M vs $180.3M estimates and adjusted EPS of $0.91 vs $0.61, citing demand for BAQSIMI and Primatene MIST and the launch of ipratropium bromide. Analysts asked about R&D/SG&A, IMS FDA warning letter, business development, and margins for insulin aspart biosimilar.

PRINS RICHARD K sold 7,973 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $20.30 ($0.16M total) on 2026-08-11.

Amphastar Pharmaceuticals said it expects higher operating expenses in coming quarters due to remediation costs at its IMS facility, partly offset by shifting capital spending from other sites. Management highlighted progress in its development pipeline, including an insulin aspart biosimilar targeted for commercialization in 2027, and expects mid- to high-single-digit sales growth despite competition.

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2026 results with revenue up 5.4% year on year to $183.9 million, exceeding Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $0.91, up from $0.85, and 48.3% above consensus. The stock rose 4.5% to $20.70 after the release.

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 amph-20260806xex99d1.htm EX-99.1 EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 ​ - Net revenues of $183.9 million for the three months ended June 30, 2026 ​ - GAAP net income of $30.3 million, or $0.67 per sh

Amphastar Pharmaceuticals (NASDAQ: AMPH) said it will report second-quarter 2026 results for the period ended June 30, 2026 after the market closes on Aug. 6, 2026, and hold a conference call at 2:00 p.m. Pacific. A webcast replay will be posted on the company’s investor site within 24 hours.

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Amphastar Pharmaceuticals, Inc._July 9, 2026 0001297184 false 0001297184 2026-07-09 2026-07-09 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ​ ​ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ​ Date of

The FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray by Amphastar Pharmaceuticals, for over-the-counter sale on June 16, 2026. It joins Narcan (Emergent BioSolutions) and RiVive (Harm Reduction Therapeutics) as OTC naloxone options. The article cites overdose-death figures and says expanded access may affect retail pricing and availability.